A Fatal Breakthrough COVID-19 Case Following Bendamustine-Rituximab Therapy

Although messenger ribonucleic acid vaccines are substantially effective toward SARS-CoV-2 infection, patients with hematologic malignancies are still prone to the virus. Herein, we report a fatal case of breakthrough SARS-CoV-2 Delta variant infection in a patient with mucosa-associated lymphoid ti...

Descripción completa

Detalles Bibliográficos
Autores principales: Kamegai, Kohei, Iwamoto, Noriko, Togano, Tomiteru, Maeda, Kenji, Takamatsu, Yuki, Miyazato, Yusuke, Ishikane, Masahiro, Mizokami, Masashi, Sugiyama, Masaya, Iida, Shun, Miyamoto, Sho, Suzuki, Tadaki, Ohmagari, Norio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9054701/
https://www.ncbi.nlm.nih.gov/pubmed/35500795
http://dx.doi.org/10.1016/j.ijid.2022.04.058
_version_ 1784697249598537728
author Kamegai, Kohei
Iwamoto, Noriko
Togano, Tomiteru
Maeda, Kenji
Takamatsu, Yuki
Miyazato, Yusuke
Ishikane, Masahiro
Mizokami, Masashi
Sugiyama, Masaya
Iida, Shun
Miyamoto, Sho
Suzuki, Tadaki
Ohmagari, Norio
author_facet Kamegai, Kohei
Iwamoto, Noriko
Togano, Tomiteru
Maeda, Kenji
Takamatsu, Yuki
Miyazato, Yusuke
Ishikane, Masahiro
Mizokami, Masashi
Sugiyama, Masaya
Iida, Shun
Miyamoto, Sho
Suzuki, Tadaki
Ohmagari, Norio
author_sort Kamegai, Kohei
collection PubMed
description Although messenger ribonucleic acid vaccines are substantially effective toward SARS-CoV-2 infection, patients with hematologic malignancies are still prone to the virus. Herein, we report a fatal case of breakthrough SARS-CoV-2 Delta variant infection in a patient with mucosa-associated lymphoid tissue lymphoma with remission by bendamustine-rituximab (BR) therapy completed a year ago. The serologic study revealed impaired responsiveness toward vaccines and prolonged high viral load after infection. BR therapy seemingly induced an immune escape. Prevention and treatment strategies for such vulnerable patients should be clarified immediately.
format Online
Article
Text
id pubmed-9054701
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
record_format MEDLINE/PubMed
spelling pubmed-90547012022-05-02 A Fatal Breakthrough COVID-19 Case Following Bendamustine-Rituximab Therapy Kamegai, Kohei Iwamoto, Noriko Togano, Tomiteru Maeda, Kenji Takamatsu, Yuki Miyazato, Yusuke Ishikane, Masahiro Mizokami, Masashi Sugiyama, Masaya Iida, Shun Miyamoto, Sho Suzuki, Tadaki Ohmagari, Norio Int J Infect Dis Article Although messenger ribonucleic acid vaccines are substantially effective toward SARS-CoV-2 infection, patients with hematologic malignancies are still prone to the virus. Herein, we report a fatal case of breakthrough SARS-CoV-2 Delta variant infection in a patient with mucosa-associated lymphoid tissue lymphoma with remission by bendamustine-rituximab (BR) therapy completed a year ago. The serologic study revealed impaired responsiveness toward vaccines and prolonged high viral load after infection. BR therapy seemingly induced an immune escape. Prevention and treatment strategies for such vulnerable patients should be clarified immediately. The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2022-08 2022-04-30 /pmc/articles/PMC9054701/ /pubmed/35500795 http://dx.doi.org/10.1016/j.ijid.2022.04.058 Text en © 2022 The Author(s) Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Kamegai, Kohei
Iwamoto, Noriko
Togano, Tomiteru
Maeda, Kenji
Takamatsu, Yuki
Miyazato, Yusuke
Ishikane, Masahiro
Mizokami, Masashi
Sugiyama, Masaya
Iida, Shun
Miyamoto, Sho
Suzuki, Tadaki
Ohmagari, Norio
A Fatal Breakthrough COVID-19 Case Following Bendamustine-Rituximab Therapy
title A Fatal Breakthrough COVID-19 Case Following Bendamustine-Rituximab Therapy
title_full A Fatal Breakthrough COVID-19 Case Following Bendamustine-Rituximab Therapy
title_fullStr A Fatal Breakthrough COVID-19 Case Following Bendamustine-Rituximab Therapy
title_full_unstemmed A Fatal Breakthrough COVID-19 Case Following Bendamustine-Rituximab Therapy
title_short A Fatal Breakthrough COVID-19 Case Following Bendamustine-Rituximab Therapy
title_sort fatal breakthrough covid-19 case following bendamustine-rituximab therapy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9054701/
https://www.ncbi.nlm.nih.gov/pubmed/35500795
http://dx.doi.org/10.1016/j.ijid.2022.04.058
work_keys_str_mv AT kamegaikohei afatalbreakthroughcovid19casefollowingbendamustinerituximabtherapy
AT iwamotonoriko afatalbreakthroughcovid19casefollowingbendamustinerituximabtherapy
AT toganotomiteru afatalbreakthroughcovid19casefollowingbendamustinerituximabtherapy
AT maedakenji afatalbreakthroughcovid19casefollowingbendamustinerituximabtherapy
AT takamatsuyuki afatalbreakthroughcovid19casefollowingbendamustinerituximabtherapy
AT miyazatoyusuke afatalbreakthroughcovid19casefollowingbendamustinerituximabtherapy
AT ishikanemasahiro afatalbreakthroughcovid19casefollowingbendamustinerituximabtherapy
AT mizokamimasashi afatalbreakthroughcovid19casefollowingbendamustinerituximabtherapy
AT sugiyamamasaya afatalbreakthroughcovid19casefollowingbendamustinerituximabtherapy
AT iidashun afatalbreakthroughcovid19casefollowingbendamustinerituximabtherapy
AT miyamotosho afatalbreakthroughcovid19casefollowingbendamustinerituximabtherapy
AT suzukitadaki afatalbreakthroughcovid19casefollowingbendamustinerituximabtherapy
AT ohmagarinorio afatalbreakthroughcovid19casefollowingbendamustinerituximabtherapy
AT kamegaikohei fatalbreakthroughcovid19casefollowingbendamustinerituximabtherapy
AT iwamotonoriko fatalbreakthroughcovid19casefollowingbendamustinerituximabtherapy
AT toganotomiteru fatalbreakthroughcovid19casefollowingbendamustinerituximabtherapy
AT maedakenji fatalbreakthroughcovid19casefollowingbendamustinerituximabtherapy
AT takamatsuyuki fatalbreakthroughcovid19casefollowingbendamustinerituximabtherapy
AT miyazatoyusuke fatalbreakthroughcovid19casefollowingbendamustinerituximabtherapy
AT ishikanemasahiro fatalbreakthroughcovid19casefollowingbendamustinerituximabtherapy
AT mizokamimasashi fatalbreakthroughcovid19casefollowingbendamustinerituximabtherapy
AT sugiyamamasaya fatalbreakthroughcovid19casefollowingbendamustinerituximabtherapy
AT iidashun fatalbreakthroughcovid19casefollowingbendamustinerituximabtherapy
AT miyamotosho fatalbreakthroughcovid19casefollowingbendamustinerituximabtherapy
AT suzukitadaki fatalbreakthroughcovid19casefollowingbendamustinerituximabtherapy
AT ohmagarinorio fatalbreakthroughcovid19casefollowingbendamustinerituximabtherapy

Ejemplares similares